James O'Neil Topline Summary and Update The market has been much more confident in the outlook for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) than I was in my first coverage of the company back in December immediately following their first drug approval. Indeed, multiple analysts have since presented articles echoing that SWTX maintains an unclear risk to reward potential, given the potential market size for their main drug relative to the multi-billion dollar market valuation. Today, we have the first tr ...